Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) and Oncocyte (NASDAQ:IMDX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk and valuation.
Insider and Institutional Ownership
64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 55.3% of Oncocyte shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by company insiders. Comparatively, 2.2% of Oncocyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Werewolf Therapeutics and Oncocyte”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Werewolf Therapeutics | $1.88 million | 26.14 | -$60.82 million | ($0.76) | -1.33 |
| Oncocyte | $4.05 million | 24.24 | -$50.22 million | ($1.49) | -2.01 |
Oncocyte has higher revenue and earnings than Werewolf Therapeutics. Oncocyte is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Werewolf Therapeutics and Oncocyte, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Werewolf Therapeutics | 1 | 3 | 2 | 1 | 2.43 |
| Oncocyte | 1 | 0 | 2 | 0 | 2.33 |
Werewolf Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 295.65%. Oncocyte has a consensus price target of $10.50, indicating a potential upside of 250.00%. Given Werewolf Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Werewolf Therapeutics is more favorable than Oncocyte.
Volatility & Risk
Werewolf Therapeutics has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, Oncocyte has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500.
Profitability
This table compares Werewolf Therapeutics and Oncocyte’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Werewolf Therapeutics | N/A | -166.99% | -59.88% |
| Oncocyte | -2,955.63% | N/A | -107.52% |
Summary
Werewolf Therapeutics beats Oncocyte on 10 of the 14 factors compared between the two stocks.
About Werewolf Therapeutics
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
About Oncocyte
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
